EUVIMEDEUVIMED entdecken
Crossref

Respiratory Viral Infections Following CD19 CAR T‐Cell Therapy

Julian J Weiss, Julia Messina, Jennifer Saullo, Yan Li, Tessa M Andermann, Melody Smith, Daniel Schrum iD, Erin Eberwein, Erin Kennedy, Krista Rowe-Nichols, Christopher Kelsey, Taewoong Choi und 3 weitere

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.70941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Julian J Weiss und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Immunotherapy, Adoptive, Antigens, CD19, Virus Diseases. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory viral infections (RVI) are an important infectious complication after chimeric antigen receptor (CAR) T‐cell therapy. However, the epidemiology of RVI following CAR T‐cell therapy and their risk factors are not well defined. To describe the incidence, epidemiology, and clinical characteristics of RVI in patients who have received CD19 CAR T‐cell therapy and identify independent risk factors for infection, we performed a retrospective, single‐center cohort study including 101 patients treated with CD19 CAR T‐cell therapy between April 2018 and January 2023. Demographic, clinical, and infection characteristics were recorded and compared among patients who did and did not develop RVI within 18 months of CAR T‐cell infusion. Logistic regression was performed to assess for predictors of RVI. Among the 101 CAR T‐cell recipients, 32 RVIs were diagnosed in 21 individuals (20.8%) for an infection density of 34 infections/100 person‐years. SARS‐CoV‐2 was the most common cause of RVI (17, 53.1%). Infection severity was usually mild (56%) or moderate (41%) with only 1 patient developing severe RVI. We found that elevated BMI was associated with higher odds of RVI (OR 1.13, 95% CI 1.04, 1.23). This study provides detailed information on the clinical characteristics of RVI in patients following CAR T‐cell therapy. RVI were a common complication following CAR T‐cell therapy, but tended to be mild in severity and generally decreased in frequency with time. Larger prospective studies will be necessary to fully characterize risk factors for RVI and interventions that may reduce their incidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsImmunotherapy, AdoptiveAntigens, CD19Virus DiseasesHumansFemaleMiddle AgedRetrospective StudiesMaleRisk FactorsAdultIncidenceAgedReceptors, Chimeric AntigenCOVID-19SARS-CoV-2

Stichwörter der Autor:innen

CAR T‐cell therapyinfectious complicationsrespiratory viral infection

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
  • Duke Cancer Institute Biostatistics Shared Resource, Duke University, Durham, North Carolina, USA.
  • Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, USA.
  • Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Daniel Schrum, Jonathan Huggins

Zitieren

APA

Weiss, J. J., Messina, J., Saullo, J., Li, Y., Andermann, T. M., Smith, M., Schrum, D., Eberwein, E., Kennedy, E., Rowe-Nichols, K., Kelsey, C., Choi, T., McKinney, M., Kang, Y., & Huggins, J. (2026). Respiratory Viral Infections Following CD19 CAR T‐Cell Therapy. Journal of Medical Virology. https://doi.org/10.1002/jmv.70941

Vancouver

Weiss JJ, Messina J, Saullo J, Li Y, Andermann TM, Smith M, et al. Respiratory Viral Infections Following CD19 CAR T‐Cell Therapy. Journal of Medical Virology. 2026. doi:10.1002/jmv.70941

BibTeX
@article{Weiss2026,
  author = {Weiss, Julian J and Messina, Julia and Saullo, Jennifer and Li, Yan and Andermann, Tessa M and Smith, Melody and Schrum, Daniel and Eberwein, Erin and Kennedy, Erin and Rowe-Nichols, Krista and Kelsey, Christopher and Choi, Taewoong and McKinney, Matthew and Kang, Yubin and Huggins, Jonathan},
  title = {Respiratory Viral Infections Following CD19 CAR T‐Cell Therapy},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.70941}
}
Kostenlos starten →